Clinical trials: Major Adverse Cardiac Event (MACE)
Hypercholesterolemia
The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment
Prospective Observation study to identify the rate of MACE in AMI with Livalo V(Pitavastatin/Valsartan) for 12 month in Korea
- Trial name
- LAMISIII (NCT04270344)
- Testing
- Pitavastatin 4mg
- Where
- South Korea
- Volunteers
- 905 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
MACE, Cardiac Death
Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform
The goal of this observational study is to observe the characteristics of cardiopulmonary exercise testing (CPET) parameters in patients across different cardiovascular diseases and to evaluate the predictive value of…
- Conditions
- MACE, Cardiac Death, Unplanned Repeat Revascularization, Cardiac Rehospitalization
- Trial name
- China-CPET (NCT07130968)
- Where
- China
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
MACE, Atrial Fibrillation (AF)
throMboembolic Risk Associated To High atrIal Fibrillation riSk
Cardiovascular diseases are the leading cause of mortality from treatable conditions in the European Union and the second from preventable causes, with a standardized mortality rate of 257.8 deaths per 100,000 inhabitants.
- Conditions
- MACE, Atrial Fibrillation (AF), Quality-adjusted Life-years, Electronic Health Records
- Trial name
- MATHIAS (NCT07441759)
- Testing
- AI_MATHIAS
- Where
- Spain
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Major Adverse Cardiac Event (MACE)
How Clinical and Personal Information Shape Physicians' Risk Judgments
Physicians often form quick judgments about the risk for serious disease when interacting with patients. Underestimating risk can lead to underuse of diagnostic testing and untreated illness, which can worsen patient outcomes.
- Trial name
- NCT07162376
- Testing
- Personal Information Disclosure
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Myocarditis
Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine
This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.
- Trial name
- MACIS (NCT05438472)
- Testing
- data collection in healthcare professionals with COVID-19 mRNA vaccine booster
- Where
- Switzerland
- Volunteers
- 835 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland